← Leaderboards
Lawrence G. Hunsicker
University Of Iowa
$454,940
Attributed
$454,940
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $65.5K · FY2005–07$100K$75K$50K$25K$0
'05
'06
'07
Funding mix
By agency
NIH$454,940 · 6
By mechanism
M01$253,477 · 5
N01$201,463 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Iowa
Same institution · by research overlap
- Steven R Lentz$22,602,998
- Frank M Faraci$14,285,039
- William G Haynes$5,096,085
- Lyndsay Anne Harshman$2,266,374
- Ronald M Lauer$4,564,247
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHypertensionProteinuriaInhibitor /AntagonistNoninsulin Dependent Diabetes MellitusAntihypertensive AgentsAngiotensinsDrug Adverse EffectHormone ReceptorDrug InteractionsIrbesartanDrug Screening /EvaluationProspectiveInstitutionKidney TransplantationResearch PersonnelCardiovascular Disorder RiskHomocysteineIncidenceComputer Retrieval Of Information On Scientific Projects DatabaseFundingGrantResources
Grant awards (9)
FOLIC ACID FOR VASCULAR OUTCOME REDUCTION IN TRANSPLANTATION (FAVORIT)$22,793
M01 · FY2007 · RR · contact PI
LONG-TERM DETERIORATION OF KIDNEY ALLOGRAFT FUNCTION (DEKAF)$2,171
M01 · FY2007 · RR · contact PI
FOLIC ACID FOR VASCULAR OUTCOME REDUCTION IN TRANSPLANTATION (FAVORIT)$65,514
M01 · FY2006 · RR · contact PI
FOLIC ACID FOR VASCULAR OUTCOME REDUCTION IN TRANSPLANTATION (FAVORIT)$48,885
M01 · FY2005 · RR
Folic Acid for Vascular Outcome Reduction in Transplant$92,086
M01 · FY2004 · RR
SAFETY AND EFFACY OF IRBESARTAN IN HYPERTENSIVE TYPE II DIABETICS$0
M01 · FY2002 · RR
SAFETY AND EFFACY OF IRBESARTAN IN HYPERTENSIVE TYPE II DIABETICS$0
M01 · FY2001 · RR
US RENAL DATA SYSTEM - SPECIAL STUDIES - ECONOMICS$201,463
N01 · FY2000 · DK
SAFETY AND EFFACY OF IRBESARTAN IN HYPERTENSIVE TYPE II DIABETICS$22,028
M01 · FY2000 · RR